SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-22-139450
Filing Date
2022-05-04
Accepted
2022-05-04 07:11:07
Documents
14
Period of Report
2022-05-04
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d308674d8k.htm   iXBRL 8-K 25351
2 EX-99.1 d308674dex991.htm EX-99.1 72782
6 GRAPHIC g308674g0504024627303.jpg GRAPHIC 5859
  Complete submission text file 0001193125-22-139450.txt   236066

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA mcrb-20220504.xsd EX-101.SCH 2875
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE mcrb-20220504_lab.xml EX-101.LAB 17236
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE mcrb-20220504_pre.xml EX-101.PRE 10825
8 EXTRACTED XBRL INSTANCE DOCUMENT d308674d8k_htm.xml XML 3240
Mailing Address 200 SIDNEY STREET CAMBRIDGE MA 02139
Business Address 200 SIDNEY STREET CAMBRIDGE MA 02139 617 945 9626
Seres Therapeutics, Inc. (Filer) CIK: 0001609809 (see all company filings)

IRS No.: 274326290 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37465 | Film No.: 22889804
SIC: 2834 Pharmaceutical Preparations